Zika Virus Infection: Transmission, Symptoms, and Risks

Zika virus is an enveloped RNA virus belonging to the Flaviviridae family, first identified in monkeys in the Zika Forest of Uganda in 1947. It is primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes, the same species that transmit Dengue and Chikungunya.

Although the vast majority of Zika virus infections cause mild, self-limiting symptoms or no symptoms at all, the virus is a significant public health concern due to its potential to cause severe neurological complications and congenital birth defects when contracted during pregnancy.

Zika virus can be transmitted through several distinct pathways:

• Mosquito Bites: The primary vector is the infected Aedes mosquito.
• Mother to Fetus: The virus can cross the placenta during pregnancy or transmit around the time of birth, leading to congenital Zika syndrome.
• Sexual Transmission: Zika can be passed through unprotected sex by a person infected with the virus. The virus can persist in semen for several months.
• Blood Transfusions: Though rare, transmission can occur through infected blood donations.

Approximately 80% of individuals infected with Zika virus do not show any symptoms. For those who do, symptoms are typically mild, appearing 3 to 14 days after exposure, and last for 2 to 7 days.

Common symptoms include a low-grade fever, an itchy maculopapular rash starting on the face and spreading, non-purulent conjunctivitis (red, bloodshot eyes without discharge), joint pain (primarily in the small joints of hands and feet), muscle pain, and headache.

The most severe consequence of Zika virus is its impact on pregnancy. An infection in a pregnant woman can lead to congenital Zika syndrome in the fetus, characterized by:

• Severe Microcephaly: A birth defect where the baby's head is significantly smaller than expected due to abnormal brain development.
• Brain Abnormalities: Calcium deposits (calcifications) in the brain, collapsed skull bones, and loss of brain tissue.
• Sensory and Joint Defects: Damage to the back of the eye (macular scarring), hearing loss, and restricted joint movement (arthrogryposis).

Diagnostic testing is highly recommended for symptomatic individuals who have recently traveled to active Zika transmission zones, and particularly for pregnant women with potential exposure.

Diagnosis is confirmed using molecular testing (RT-PCR) of urine or blood samples within the first two weeks after symptom onset to detect viral RNA. Beyond this period, serological testing for Zika-specific IgM antibodies is performed, though cross-reactivity with other flaviviruses like Dengue can complicate interpretation.

There is no specific antiviral medication or vaccine available for Zika virus. Management is purely supportive:

• Rest and Hydration: Get plenty of rest and drink adequate fluids to prevent dehydration.
• Fever and Pain Management: Use acetaminophen (paracetamol) to relieve fever and pain. Avoid aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) until Dengue has been ruled out to minimize bleeding risks.
• Medical Monitoring: Pregnant women with suspected or confirmed Zika exposure require close monitoring with serial ultrasounds to assess fetal growth and anatomy.

Prevention is the best defense against Zika virus. Key recommendations include:

• Vector Control: Eliminate standing water around the home to prevent mosquito breeding.
• Avoid Mosquito Bites: Use EPA-registered insect repellents, wear long sleeves and pants, and stay in screened or air-conditioned accommodations.
• Safe Sex Practices: To prevent sexual transmission, use condoms consistently or abstain from sex for 3 months (for men) or 2 months (for women) after traveling to an area with Zika transmission or after symptom onset.